Clinical Trials Logo

Herpes Simplex 1 clinical trials

View clinical trials related to Herpes Simplex 1.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04710030 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Valacyclovir for Mild Cognitive Impairment

VALMCI
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI) patients (eMCI and lMCI). The trial will directly address the long-standing viral etiology hypothesis of Alzheimer's disease (AD) which posits that viruses, particularly the very common herpes simplex virus-1 (HSV1) and herpes simplex virus-2 (HSV2), may be etiologic or contribute to the pathology of AD. This trial will intervene at an earlier stage (MCI). We will compare the repurposed drug valacyclovir to placebo in patients with amnestic MCI (eMCI and lMCI) in a randomized, double-blind, two-arm parallel group 52-week pilot trial. Our Phase II trial will be the first antiviral drug trial conducted in MCI.

NCT ID: NCT03282916 Active, not recruiting - Alzheimer Disease Clinical Trials

Anti-viral Therapy in Alzheimer's Disease

Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

Anti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex (valacyclovir, 500mg oral tablet). Valacyclovir, titrated to 4 grams per day, repurposed to treat Alzheimer's disease, will be compared to matching placebo in the treatment of 130 mild AD patients (65 valacyclovir, 65 placebo) who test positive for herpes simplex virus-1 (HSV1) or herpes simplex virus-2 (HSV2). The study will be a randomized, double-blind, 18-month Phase II proof of concept trial.